ABSTRACT
Despite advances in COVID-19 vaccine development, global immunization has proceeded slowly, with low-income countries being disadvantaged in the distribution of vaccines (York, 2020). Hence, a large portion of the global population will remain unprotected against the virus unless they strictly keep up with the prevention measures. To support the UN Sustainable Goal 3 and related targets of improving prevention efforts to promote good health and well-being, this paper shares participants' adherence to recommended prevention behaviors and their relationship to demographic characteristics, personal health beliefs, and well-being across a large, nonrandomized sample from over 60 countries. The findings indicate more variability in adherence to behaviors within countries than between them, with women and those with more education and subjective socioeconomic status being more compliant with prevention recommendations. Positive feelings toward one's ability to stay healthy impacted behavior more than fear of contracting the disease. Implications for the importance of prevention science to further positive behavior change supporting the UN Sustainable Goal of promoting health and well-being are highlighted. (PsycInfo Database Record (c) 2022 APA, all rights reserved) Impact Statement Impact and Implications.-To advance the UN Sustainable Goal 3 of promoting health and well-being, particularly among those less economically advantaged countries, we require a better understanding of how to support healthy behaviors. This study furthers our knowledge of prevention science and informs how to target interventions to help people change their behaviors to improve their health and well-being. (PsycInfo Database Record (c) 2022 APA, all rights reserved)
ABSTRACT
Recently, the stabilization of the endothelium has been explicitly identified as a therapeutic goal in coronavirus disease 2019 (COVID-19). Adrecizumab (HAM8101) is a first-in-class humanized monoclonal anti-Adrenomedullin (anti-ADM) antibody, targeting the sepsis- and inflammation-based vascular and capillary leakage. Within a "treatment on a named-patient basis" approach, Adrecizumab was administered to eight extreme-critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). The patients received a single dose of Adrecizumab, which was administered between 1 and 3 days after the initiation of mechanical ventilation. The SOFA (median 12.5) and SAPS-II (median 39) scores clearly documented the population at highest risk. Moreover, six of the patients suffered from acute renal failure, of whom five needed renal replacement therapy. The length of follow-up ranged between 13 and 27 days. Following the Adrecizumab administration, one patient in the low-dose group died at day 4 due to fulminant pulmonary embolism, while four were in stable condition, and three were discharged from the intensive care unit (ICU). Within 12 days, the SOFA score, as well as the disease severity score (range 0-16, mirroring critical resources in the ICU, with higher scores indicating more severe illness), decreased in five out of the seven surviving patients (in all high-dose patients). The PaO2/FiO2 increased within 12 days, while the inflammatory parameters C-reactive protein, procalcitonin, and interleukin-6 decreased. Importantly, the mortality was lower than expected and calculated by the SOFA score. In conclusion, in this preliminary uncontrolled case series of eight shock patients with life-threatening COVID-19 and ARDS, the administration of Adrecizumab was followed by a favorable outcome. Although the non-controlled design and the small sample size preclude any definitive statement about the potential efficacy of Adrecizumab in critically ill COVID-19 patients, the results of this case series are encouraging.